CN1333023A - Bifidoquater live bacterial chip - Google Patents
Bifidoquater live bacterial chip Download PDFInfo
- Publication number
- CN1333023A CN1333023A CN01108353A CN01108353A CN1333023A CN 1333023 A CN1333023 A CN 1333023A CN 01108353 A CN01108353 A CN 01108353A CN 01108353 A CN01108353 A CN 01108353A CN 1333023 A CN1333023 A CN 1333023A
- Authority
- CN
- China
- Prior art keywords
- intestinal
- bacillus
- bacillus cereus
- live bacterial
- bifidoquater
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to a bifidoquadruple live bacterial tablet. It is composed of infantile bifidobacteria, acidophil lactobacillus, streptococcus faecalis and bacillus cereus. The tests show that as compared with quantity of SIgA produced by preparation containing no bacillus cereus the quantity of SIgA produced by bacillus cereus synergistic bifidobacteria stimulated body immune system can be raised by 5-10 times, so that said invented product possesses high therapeutic effect for curing adult acute diarrhea, chronic diarrhea, adult constipation and infantile acute diarrhea.
Description
The invention belongs to microorganism formulation
Along with medicine biological technique constantly develops, the microbial ecological agent that contains viable bacteria is used for the treatment of some disease and has obtained great success.In recent years, the mankind have invented a class and have replenished the microorganism formulation that the normal physiological bacteria of human body is treated some intestinal tract disease by adjusting, at present, existing many microorganism formulation medicines that contain Lactobacillus lactis and other strains, as the Le Kefoluo (Laotiflora Soucher) of France, be the preparation that contains bacillus acidophilus and lactobacillus casei; Useful (the Inflora Bema) of Switzerland is to contain lactobacillus casei and enterococcal preparation; Domestic whole intestinal is given birth to and is single bifidobacterium adolescentis; Birid Triple Viable is bifidobacterium bifidum, bacillus acidophilus and streptococcus faecalis three strain bacteria preparations; Other, ANGLI No. 1 strange as sky three etc. is three strain bacteria preparations.These preparations have the effect of additional human body normal physiological antibacterial, diarrhoea and constipation that treatment colitis, dysbacteriosis are caused have unique effect, but aforesaid bacillus bifidus and some bacterial strains all are obligate anaerobes, their field planting in intestinal need an anaerobic environment, and human body intestinal canal is a little oxygen environment, so some above-mentioned bacillus are in the intestinal difficulty that is implanted with decided at the higher level but not officially announced, therefore cause strain viability in intestinal bad, the time of staying is short, discharge easily, cause the curative effect of preparation to be affected.
The object of the present invention is to provide microbial ecological agent one Bifidoquater live bacterial chip of the treatment intestinal tract disease that the field planting in intestinal of a kind of strain is better, curative effect is high.
The present invention is made up of bifidobacteria infantis (Bifidobacterium infantis), bacillus acidophilus (Lactobacillus acidophilus), streptococcus faecalis (Streptococcus faecalis) and four kinds of strains of bacillus cereus (Bacillus cereus) that (above-mentioned culture presevation is at the common biological center of Chinese microbial preservation administration committee, address: BeiJing ZhongGuanCun, preservation date: on June 20th, 2000, deposit number: bifidobacteria infantis 0460.1, bacillus acidophilus 0460.2, streptococcus faecalis 0460.3, bacillus cereus 0460.4).To keep certain equilibrium relation between the microorganism of human organism inside (comprising kind, character, quantity, structure distribution etc.) and its living environment (human body), it is microecological balance, microorganism in the human body intestinal canal has kind more than 400, wherein bacillus bifidus, bacillus acidophilus, streptococcus faecalis account for more than 98%, and all the other are antibacterial and harmful bacterium of the state of mediating.Under the normal condition, relative balance state between probiotics, conditioned pathogen, the harmful bacterium, be subjected to factor affecting such as environment, weather, diet, medication, emotion when body, the mediate bacterium of state of intestinal will be transformed into pathogenic bacterium, harmful simultaneously bacterium can breed in a large number, make intestinal microecology system disequilibrium, thereby produce intestinal tract disease.The present invention can replenish the normal physiological antibacterial of human body intestinal canal, recovers intravital microecological balance.Bacillus bifidus is probiotics, objective reality is participated in the formation of digestive tract film flora directly, bacillus bifidus interacts by teichoic acid and intestinal epithelial cell, combination closely, and occupy the intestinal mucosa surface jointly with other anaerobe, form biological barrier, stop field planting and the intrusion of pathogenic bacterium, conditioned pathogen.In addition, bacillus bifidus produces acid in metabolic process, make intestinal be in sour environment, keeps the normal creepage of gastrointestinal functions of intestinal, stops pathogenic bacterium field planting and suppress the pathogenic bacterium growth in intestinal.Bacillus bifidus also synthetic multivitamin, human body immunity improving ability of tool, suppress tumor cell, improve effect such as sclerosis of blood vessels.Bacillus acidophilus's energy synthetic vitamin assist digestion food helps alimentation, enhances metabolism.This bacterium produces acid in intestinal, collaborative bacillus bifidus suppresses harmful bacterium, overcomes decay process, reduces harmful substance and produces, and quickens the eliminating of harmful substance.This bacterium can also reduce the body cholesterol, and enhancing body is to the endurance of lactic acid.The field planting of the excrement coccobacillus is in the outermost layer of film flora at lower intestinal tract, is the measuring device of health sensitivity, and when flora took place by extensive the change, streptococcus faecalis at first changed, and consumes outermost biological barrier, makes intestinal be in unbalanced state.Therefore, the effect of streptococcus faecalis is exactly to constitute the outer biological barrier of intestinal, makes it be in poised state.Bacillus cereus is an important composition content of the present invention, bacillus bifidus is an obligate anaerobe, its field planting in intestinal needs an anaerobic environment, and human body intestinal canal is not to be an oxygen-free environment, so in general, bacillus bifidus field planting in intestinal is inconvenient, this just general not good enough main cause of microorganism formulation drug effect.Bacillus cereus is a facultative anaerobe, do not belong to normal physiological bacterium in the intestinal, belong to " bacterium passes by on one's way " (excreting in general oral back 48 hours), but this bacterium is the antibacterial of oxygen consumption maximum, it can consume local molecular oxygen in the intestinal in a large number, make the enteral environment be tending towards anaerobic state, so just more help the growth of the field planting of bacillus bifidus.
Because the present invention has adopted bacillus cereus, thereby make curative effect of the present invention be higher than other like products, simultaneously, evidence, the amount ratio of the collaborative bacillus bifidus stimulation of the bacillus cereus body immune system generation SIgA or not amount of of the preparation generation of content of wax sample bacillus cereus improves 5-10 times.Bifidobacteria infantis of the present invention separates from Chinese healthy children feces, screens, cultivates, and except that the identical characteristics with other bacillus bifiduss, its physiologically active is stronger, and richer vitality is that other bacillus bifiduss can not be compared.Bacillus acidophilus, streptococcus faecalis are all separated from China's Healthy people specimen, compare with the foreign strain that more above-mentioned domestic and international preparations are used, are more suitable for better playing a role in field planting in Chinese's intestinal.
Clinical research shows, the present invention is to adult's acute diarrhea, chronic diarrhea, adult's constipation, infantile acute diarrheas etc. have good curative effect, wherein the total effective rate to adult's acute diarrhea is 89.9%, be higher than 8 percentage points of other drugs, total effective rate to adult's chronic diarrhea is 87.76%, be higher than 14 percentage points of other drugs, total effective rate to adult's constipation is 83.16%, be higher than 13 percentage points of other medicines, portion's effective percentage to infantile acute diarrhea is 89.00%, is higher than 12 percentage points of other drugs.
Embodiment
Four kinds of bacterium are made mycopowder after inoculation, cultivation, lyophilizing, adjust, granulate, be pressed into lamellar, wherein every gram tablet contains bifidobacteria infantis 5.0 * 10
6Individual; The bacillus acidophilus 2.5 * 10
5Individual: streptococcus faecalis 2.5 * 10
5Individual: bacillus cereus 2.5 * 10
5Individual.
Claims (2)
1, Bifidoquater live bacterial chip is characterized in that it is made up of bifidobacteria infantis, bacillus acidophilus, streptococcus faecalis and four kinds of strains of bacillus cereus.
2,, it is characterized in that containing bifidobacteria infantis 5.0 * 10 in every gram tablet according to the said Bifidoquater live bacterial chip of claim 1
6Individual; The bacillus acidophilus is 2.5 * 10
6Individual; Streptococcus faecalis 2.5 * 10
6Individual; Bacillus cereus 2.5 * 10
5Individual.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN01108353A CN1121864C (en) | 2000-07-06 | 2001-02-23 | Bifidoquater live bacterial chip |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00110621.X | 2000-07-06 | ||
| CN00110621 | 2000-07-06 | ||
| CN01108353A CN1121864C (en) | 2000-07-06 | 2001-02-23 | Bifidoquater live bacterial chip |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1333023A true CN1333023A (en) | 2002-01-30 |
| CN1121864C CN1121864C (en) | 2003-09-24 |
Family
ID=25739341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN01108353A Expired - Lifetime CN1121864C (en) | 2000-07-06 | 2001-02-23 | Bifidoquater live bacterial chip |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1121864C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011069860A1 (en) * | 2009-12-08 | 2011-06-16 | Chr. Hansen A/S | Novel use for the treatment of metabolic endotoxemia |
| CN101874812B (en) * | 2010-05-14 | 2012-05-23 | 薛恒平 | Composite bacteria preparation and application thereof in weight increment of immature livestock and control of diarrhea |
| CN104522648A (en) * | 2014-12-18 | 2015-04-22 | 杭州龙达新科生物制药有限公司 | Tetragenus probiotic preparation and application thereof |
| CN105878295A (en) * | 2016-03-31 | 2016-08-24 | 黄芳 | Compound for efficiently clearing stubborn stool in stomach and intestines as well as preparation method and application of compound |
| CN113116939A (en) * | 2019-12-31 | 2021-07-16 | 杭州远大生物制药有限公司 | Microbial preparation and preparation method thereof |
| CN113925886A (en) * | 2021-09-28 | 2022-01-14 | 杭州远大生物制药有限公司 | New application of tetrad live bacteria composition |
| CN115227728A (en) * | 2022-05-31 | 2022-10-25 | 湖南航天医院 | Intestinal microecological preparation and preparation method thereof |
| CN115478025A (en) * | 2021-06-15 | 2022-12-16 | 杭州远大生物制药有限公司 | Probiotic compositions and uses thereof |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101244090B (en) * | 2007-02-16 | 2011-12-28 | 信谊药厂 | Long bifidobacterium culture medium, preparation and technique |
| CN102204679B (en) * | 2011-06-16 | 2013-01-30 | 内蒙古普泽生物制品有限责任公司 | Quadruple bacterial tablets and preparation method thereof |
| CN107050065B (en) * | 2017-03-31 | 2021-03-30 | 杭州远大生物制药有限公司 | New application of bifidobacterium tetragenous live bacteria composition |
| CN108567801B (en) * | 2018-07-13 | 2020-01-21 | 海南美乐康药业有限公司 | Oral rehydration salt and preparation method and application thereof |
-
2001
- 2001-02-23 CN CN01108353A patent/CN1121864C/en not_active Expired - Lifetime
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011069860A1 (en) * | 2009-12-08 | 2011-06-16 | Chr. Hansen A/S | Novel use for the treatment of metabolic endotoxemia |
| CN101874812B (en) * | 2010-05-14 | 2012-05-23 | 薛恒平 | Composite bacteria preparation and application thereof in weight increment of immature livestock and control of diarrhea |
| CN104522648A (en) * | 2014-12-18 | 2015-04-22 | 杭州龙达新科生物制药有限公司 | Tetragenus probiotic preparation and application thereof |
| CN105878295A (en) * | 2016-03-31 | 2016-08-24 | 黄芳 | Compound for efficiently clearing stubborn stool in stomach and intestines as well as preparation method and application of compound |
| CN113116939A (en) * | 2019-12-31 | 2021-07-16 | 杭州远大生物制药有限公司 | Microbial preparation and preparation method thereof |
| CN115478025A (en) * | 2021-06-15 | 2022-12-16 | 杭州远大生物制药有限公司 | Probiotic compositions and uses thereof |
| CN113925886A (en) * | 2021-09-28 | 2022-01-14 | 杭州远大生物制药有限公司 | New application of tetrad live bacteria composition |
| CN113925886B (en) * | 2021-09-28 | 2024-02-02 | 杭州远大生物制药有限公司 | New application of tetrad viable bacteria composition |
| CN115227728A (en) * | 2022-05-31 | 2022-10-25 | 湖南航天医院 | Intestinal microecological preparation and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1121864C (en) | 2003-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100386427C (en) | Bifidobacterium and products contg same | |
| Anukam et al. | Probiotics: 100 years (1907–2007) after Elie Metchnikoff’s observation | |
| EP1539927B1 (en) | Probiotic bacterium: lactobacillus fermentum | |
| EP2000530B1 (en) | Composition of lactobacillus strains and the application of the composition of lactobacillus strains | |
| Bouvier et al. | Effects of consumptionof a milk fermented by the probiotic strain bifidobacterium animalis DN-173 010 on colonic transit times in healthy humans | |
| US7901925B2 (en) | Lactobacillus delbrueckii ssp. bulgaricus strain and compositions | |
| US20030118571A1 (en) | Oral administration of lactobacillus for the maintenance of health in women during pregnancy and at other life stages, to reduce the risk of urogenital diseases | |
| KR19990035918A (en) | A dietary composition for enteric bowel, comprising Streptococcus thermophilus and Bifidobacterium longum | |
| Amagase | Current marketplace for probiotics: a Japanese perspective | |
| TW201032733A (en) | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin | |
| CN1121864C (en) | Bifidoquater live bacterial chip | |
| CN110521939A (en) | A kind of probiotics fermention food and preparation method thereof adjusting intestinal health | |
| CN110692885A (en) | Probiotic health-care beverage for relieving constipation | |
| Rambaud et al. | Manipulation of the human gut microflora | |
| Lokhande et al. | A systematic study of probiotics-an update review | |
| US20110177126A1 (en) | Bacteria and derived products to reinforce the body defences and to reduce the risk of disease | |
| Arora et al. | Therapeutic potential of probiotics: A ray of hope or nightmare? | |
| US20090110663A1 (en) | Method for treatment of bowel disorders | |
| Figueiredo et al. | Probiotics in human health | |
| CN112006285A (en) | Targeted planting probiotic powder and preparation method thereof | |
| Singh et al. | Role of functional foods in periodontal health and disease | |
| Harsh et al. | Role of Probiotics in Human Health | |
| Das et al. | Metabolic and potential health benefits of nutraceuticals on gut microbiome | |
| BG112471A (en) | Immunomodulating synbiotic composition | |
| Reddy et al. | Probiotics-the next saviour in oral diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: LIU WEI Free format text: FORMER OWNER: BIOCHEMICAL PHARMACEUTICAL CO., LTD., JILIN WEITE GROUP Effective date: 20031205 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20031205 Address after: Hangzhou City, Zhejiang province 310005 Moganshan Road, building 503 room 6 Patentee after: Liu Wei Address before: 130012 Torch Road 8, hi tech Industrial Development Zone, Jilin, Changchun Patentee before: Biochemical Pharmaceutical Co., Ltd., Jilin Prov. Weite Group |
|
| ASS | Succession or assignment of patent right |
Owner name: HANGZHOU LONGDA XINKE BIOPHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LIU WEI Effective date: 20080718 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20080718 Address after: No. nine, 63 Ring Road, Jianggan science and Technology Economic Zone, Zhejiang, Hangzhou Patentee after: HANGZHOU LONGDA XINKE BIOLOGICAL PHARMACEUTICAL CO., LTD. Address before: Hangzhou City, Zhejiang Province, 6 Moganshan Road Building 503 room Patentee before: Liu Wei |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Bifidoquater live bacterial chip Effective date of registration: 20100511 Granted publication date: 20030924 Pledgee: Bank of Hangzhou Limited by Share Ltd science and Technology Branch Pledgor: HANGZHOU LONGDA XINKE BIOLOGICAL PHARMACEUTICAL CO., LTD. Registration number: 2010990000750 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20110325 Granted publication date: 20030924 Pledgee: Bank of Hangzhou Limited by Share Ltd science and Technology Branch Pledgor: HANGZHOU LONGDA XINKE BIOLOGICAL PHARMACEUTICAL CO., LTD. Registration number: 2010990000750 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Bifidoquater live bacterial chip Effective date of registration: 20110325 Granted publication date: 20030924 Pledgee: Bank of Hangzhou Limited by Share Ltd science and Technology Branch Pledgor: HANGZHOU LONGDA XINKE BIOLOGICAL PHARMACEUTICAL CO., LTD. Registration number: 2011990000094 |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 310019, No. nine, 63 Ring Road, Jianggan science and Technology Economic Zone, Hangzhou, Zhejiang Patentee after: Hangzhou Yuanda Biological Pharmaceutical Co., Ltd. Address before: 310019, No. nine, 63 Ring Road, Jianggan science and Technology Economic Zone, Hangzhou, Zhejiang Patentee before: HANGZHOU LONGDA XINKE BIOLOGICAL PHARMACEUTICAL CO., LTD. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20030924 |